Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. - Wikidata - awgldk - TriplyDB

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

http://www.wikidata.org/entity/Q35099127

about

Targeting molecular resistance in castration-resistant prostate cancer Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Targeting the adaptive molecular landscape of castration-resistant prostate cancer Emerging data on androgen receptor splice variants in prostate cancer Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.Taxane anticancer agents: a patent perspective.Androgen receptor aberrations in the era of abiraterone and enzalutamide.Chemotherapy in Prostate Cancer.Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.RB Loss Promotes Prostate Cancer Metastasis.The molecular underpinnings of prostate cancer: impacts on management and pathology practice.Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer.Differential impact of RB status on E2F1 reprogramming in human cancer.ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.Precision Medicine and Men's Health.Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.Prioritizing precision medicine for prostate cancer Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants A patient-derived explant (PDE) model of hormone-dependent cancer

P2860

Q26795445-D721E4BE-4484-4DCA-95EC-D78E3D02BBB6 Q26795625-F2C25259-FA97-4151-830D-3AFDEDAA172C Q26796704-DDF0C054-E5E9-4DCF-B0F2-6E23AA1D2F21 Q27022821-8E9FD55B-E4B6-4744-A0EE-2265F40D7D9D Q28077830-E8E7945A-7C7F-4F51-8D33-8C6188DD753E Q28117805-AB11E676-B5F6-44C5-961E-1178085B5463 Q30244818-7812871B-F00B-437C-A945-022161BD5C7F Q33789192-9BB2DFE5-E602-4E8B-B715-51162BE6DE2C Q35956276-F63EA830-F157-40FB-B654-4E991C783780 Q36004694-EBD8C2D7-826F-4CC5-831F-042DC8FB857B Q36410270-A7374584-228E-436D-B8CF-7DAD40C5BE85 Q36592309-6F5F03D8-511E-48B4-92B3-8626D7608569 Q37087888-1B36AADB-9622-4524-831F-3D7A62CDE9DD Q38534949-3592EC1E-A74E-40F2-A180-D1B42E001F5C Q38555599-0FDB6DCD-21CC-4A72-B802-7E1A167FD03C Q38607675-3AC1C9E3-996E-48F9-A8DB-27D5E0DC34B0 Q38727367-2B37E229-2DF3-4DC9-A098-60EA7416D9DA Q38983790-E1AD9BA8-F213-4B73-B4FF-6A269CB94A66 Q40656134-FEF0CF0B-690E-4B22-BF78-0EC5633AECEE Q41829738-8881B725-10F0-44BE-B78C-5DE3225841C5 Q41866064-10ABA95C-C5B1-4E3C-BA0B-EC10C6ABA012 Q46068832-7CD5E229-32AE-4FC4-AD8A-07279A7B345F Q46495734-3EABEA3C-630F-45D4-853A-932B0B87F320 Q47151829-2052699C-F1EF-47C0-BB82-A65B3FA62F7F Q48037116-03FAF370-8E0A-4DE0-9276-DFD28F9A9FED Q51465026-9E6BE645-04F5-4918-8007-60EB8DF559EC Q53398122-0926A58B-7E4D-45ED-B746-9D0FBBB63E94 Q53685801-637C166E-7B1F-423D-9052-692AF2EE2E13 Q53735518-C653A0FE-603F-41B9-904C-FC909AAF49F5 Q53787362-FE807FB6-A62B-45F3-B96F-9360B0615273 Q53792451-CD537EFD-1D66-4623-99B9-82B8D082DD7E Q55398521-B284CDAF-A294-4147-AE9E-7F493FDC23E0 Q55441916-2BA74D08-56B4-426D-95DD-65D5FEEC7F3D Q57693858-414A1BA1-C373-4711-866F-64ED40297B99 Q58697074-FE1D2EB0-7D8E-4C7C-A2DF-214212C8011B Q58772979-F5918605-0680-4E33-B56F-7B09B4EB96F5

P2860

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

http://www.wikidata.org/entity/Q35099127

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

@ast

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

@en

type

label

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

@ast

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

@en

prefLabel

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

@ast

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

@en

P1433

Q35099127-78EECF0B-240D-4821-AD0A-B9FBA89151D6

P1476

Q35099127-C4FE8BC9-8A48-43B7-8C6F-6ED1629F9F32

P2093

Q35099127-04C84B66-BC89-4602-BAE3-EA69D061F215

Q35099127-4339CACA-D4C4-4A57-9FAF-F108EFF6A156

Q35099127-46EAC93E-795A-4D5A-A07B-7DC63CDC1182

Q35099127-493DB792-C87F-4CD6-A1B6-5F8D53375BE6

Q35099127-AAE7AA61-3FDB-4E91-B018-7520B3E4A806

Q35099127-E80EAD2F-3DD4-4638-8564-7E910C329B20

Q35099127-F786557C-9C60-4EF7-A1E2-B3AB0819220A

P2860

Q35099127-16B73B32-971D-493F-AAAE-684396D991CA

Q35099127-1C9B1CA6-6064-4A25-9450-85E6F2F12D61

Q35099127-1DE30437-773B-4191-BB7E-304295FBECF6

Q35099127-2125DAA8-3584-45D9-AE14-3193CE853CE1

Q35099127-23597D3E-65ED-4DA5-BE12-8E1E9F4D010F

Q35099127-23C4C7FB-6167-496D-A862-BE388622DCBF

Q35099127-2ABE8A36-6B18-4762-AC68-6AF3FDF78767

Q35099127-2B122C3F-6530-4AF8-BB9A-6929145F9936

Q35099127-2F9398F3-A633-4C93-A252-8C0FF5FD53C3

Q35099127-423D6C52-8DE0-484F-BD0C-FDEC4304836A

P304

Q35099127-B3688156-0B61-4C32-93FB-23EADA30C9B2

P31

Q35099127-129A4645-0984-4593-B10A-6384BF239697

P356

Q35099127-9B139A95-1629-42DE-BD4B-791E08093A43

P407

Q35099127-81FB1513-309A-466B-95CC-4C7B0B10CEB0

P433

Q35099127-A7682B3F-FEBA-4C0D-93D0-CD80B4917440

P478

Q35099127-9281A312-0AEB-44D1-B1DA-58FC5751A07D

P50

Q35099127-297B5ABB-ABCB-4451-86FA-805B6AD00D2C

Q35099127-3C743F88-BA1A-4C5C-B36F-1DA2A0F516EB

Q35099127-43ACDB8D-8903-4DC6-BC75-BCA4976C2A48

Q35099127-A8B74CF5-D04A-4B89-98D4-A859E61BD26A

P577

Q35099127-7C4827D9-2467-4232-87A2-CF530596536F

P698

Q35099127-458C29E9-4712-45C1-B96E-5E1FAC79F791

P932

Q35099127-B83CA28B-3472-419A-AFAE-4308567FF734

P356

1078-0432.CCR-14-1358

P1433

Clinical Cancer Research

P1476

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

@en

P2093

Costas D Lallas

http://www.w3.org/2001/XMLSchema#string

Leonard G Gomella

http://www.w3.org/2001/XMLSchema#string

Lisa D Berman-Booty

http://www.w3.org/2001/XMLSchema#string

Matthew J Schiewer

http://www.w3.org/2001/XMLSchema#string

Renée de Leeuw

http://www.w3.org/2001/XMLSchema#string

Stephen J Ciment

http://www.w3.org/2001/XMLSchema#string

William K Kelly

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis

Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress

Cancer statistics, 2007

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

P304

795-807

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-1358

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Karen E Knudsen

Edouard J Trabulsi

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25691773

http://www.w3.org/2001/XMLSchema#string

P932

4333741

http://www.w3.org/2001/XMLSchema#string